Compare CTS & NRIX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CTS | NRIX |
|---|---|---|
| Founded | 1896 | 2009 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Electrical Products | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.4B | 1.6B |
| IPO Year | 1994 | 2020 |
| Metric | CTS | NRIX |
|---|---|---|
| Price | $54.64 | $16.72 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 12 |
| Target Price | N/A | ★ $30.50 |
| AVG Volume (30 Days) | 146.6K | ★ 1.3M |
| Earning Date | 04-29-2026 | 04-08-2026 |
| Dividend Yield | ★ 0.29% | N/A |
| EPS Growth | ★ 15.87 | N/A |
| EPS | ★ 2.19 | N/A |
| Revenue | ★ $541,318,000.00 | $76,987,000.00 |
| Revenue This Year | $5.55 | N/A |
| Revenue Next Year | $5.00 | $40.12 |
| P/E Ratio | $25.01 | ★ N/A |
| Revenue Growth | 4.95 | ★ 99.31 |
| 52 Week Low | $36.03 | $8.20 |
| 52 Week High | $59.66 | $22.50 |
| Indicator | CTS | NRIX |
|---|---|---|
| Relative Strength Index (RSI) | 65.50 | 58.77 |
| Support Level | $40.69 | $16.02 |
| Resistance Level | $59.66 | $16.71 |
| Average True Range (ATR) | 1.59 | 0.92 |
| MACD | 0.80 | 0.18 |
| Stochastic Oscillator | 83.21 | 82.73 |
CTS Corp operates in the electronics industry. The company is a manufacturer of Sensors, Electronic components, and Actuators. It designs, manufactures, and sells a broad line of sensors, electronic components, and actuators mainly to original equipment manufacturers (OEMs) for the aerospace and defense, industrial, information technology, medical, telecommunications, and transportation markets. Geographically, it derives a majority of its revenue from the United States and also has a presence in China, Singapore, the Czech Republic, Taiwan, Denmark, and other countries.
Nurix Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and potential commercialization of targeted protein degradation therapies for cancer and inflammatory diseases. It utilizes an integrated discovery platform that incorporates artificial intelligence and ligase expertise to support its research activities. The company's pipeline includes Bexobrutideg (NX-5948), Zelebrudomide (NX-2127), NX-1607 and BRAF degrader. These drug candidates target specific proteins involved in immune and cancer-related pathways. It operates in a single business segment.